Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Diagnostics- Switzerland

doi 10.3390/diagnostics8040076

Full Text

Abstract

Available in

Categories

Clinical Biochemistry

Date

October 31, 2018

Authors

Theodoros G. Soldatos

Antonia Dimitrakopoulou-Strauss

Lionel Larribere

Jessica C. Hassel

Christos Sachpekidis

Publisher

MDPI AG

Related search

Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Journal of Clinical Oncology

Cancer Research

English

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”

Case Reports in Oncological Medicine

English

Pcn184 - Cost-Effectiveness of Nivolumab Plus Ipilimumab in Advanced Melanoma

Value in Health

Occupational Health

English

Cost-Effectiveness of Nivolumab in Combination With Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden

Value in Health

Occupational Health

English

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-Ctla-4 Therapy in Metastatic Melanoma From the Ipilimumab Network

Multidisciplinary

English

GM-CSF/Ipilimumab Combination Extends Melanoma Survival

Cancer Discovery

English

Changing Paradigm of Immunooncology in Advanced Kidney Cancer: Nivolumab and Ipilimumab Combination in the First Line Therapy

Nuclear Medicine

English

Lung Brain Metastasis Pseudoprogression After Nivolumab and Ipilimumab Combination Treatment

Thoracic Cancer

Respiratory Medicine

English